Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs

P. David Charles, Bimal B. Padaliya, William J. Newman, Chandler E. Gill, Cassondra D. Covington, John Y. Fang, Stephanie A. So, Michael G. Tramontana, Peter E. Konrad, Thomas L. Davis

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalParkinsonism and Related Disorders
Issue number8
StatePublished - Dec 2004
Externally publishedYes


  • Antiparkinsonian medications
  • Cost analysis
  • Deep brain stimulation
  • Parkinson's disease
  • Subthalamic nucleus

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs'. Together they form a unique fingerprint.

Cite this